Document is current
Any future updates will be listed below
-
Authors
Busse, Jason W. https://orcid.org/0000-0002-0178-8712
Flood, Breanne
Madden, Kim
Kashir, Imad
Sadeghirad, Behnam
Atrey, Amit
Tardif-Theriault, Cassandra
Adili, Anthony
,
Ashoorion, Vahid
Malek, Monica
Mbuagbaw, Lawrence
Dhiman, Avneet
Ahmad, Rayan
Weerdenburg, Adam
Dagher, Danielle
Irish, Kim
Shanthanna, Harsha
Johal, Herman
Fein, Allan
Duong, Andrew
Borhan, Sayem
Wallace, Christine
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research
Michael G. DeGroote Institute for Pain Research and Care
Michael G. DeGroote Centre for Medicinal Cannabis Research
St. Joseph’s Foundation
- License Information
-
More Information
Article History
Received: 5 May 2026
Accepted: 18 August 2026
First Online: 25 August 2026
Declarations
Ethics approval and consent to participate: We received ethics approval through Clinical Trials Ontario (CTO project #3701) which provided approval for both study sites, and the Hamilton Integrated Research Ethics Board was the research ethics board on record. We received a No Objection Letter from Health Canada to conduct this trial, given that our investigational product (MPL-001) is not an approved medication in Canada. We prospectively registered our protocol on clinicaltrials.gov (NCT03825965). We conducted this study under the principles of the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practices (ICH-GCP). All participants provided written informed consent prior to participating.
Competing interests: The authors declare no competing interests.
